Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Other Operating Expenses (2016 - 2025)

BioCorRx (BICX) has disclosed Other Operating Expenses for 16 consecutive years, with -$342663.0 as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 69.63% to -$342663.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.0 million through Dec 2025, up 42.4% year-over-year, with the annual reading at -$3.0 million for FY2025, 41.6% up from the prior year.
  • Other Operating Expenses hit -$342663.0 in Q4 2025 for BioCorRx, up from -$586370.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $154586.0 in Q3 2021 to a low of -$1.5 million in Q3 2024.
  • Historically, Other Operating Expenses has averaged -$394194.5 across 5 years, with a median of $2682.5 in 2021.
  • Biggest five-year swings in Other Operating Expenses: skyrocketed 3012.08% in 2023 and later tumbled 35717.5% in 2024.
  • Year by year, Other Operating Expenses stood at $2727.0 in 2021, then soared by 228.97% to $8971.0 in 2022, then surged by 48.79% to $13348.0 in 2023, then tumbled by 8553.53% to -$1.1 million in 2024, then skyrocketed by 69.63% to -$342663.0 in 2025.
  • Business Quant data shows Other Operating Expenses for BICX at -$342663.0 in Q4 2025, -$586370.0 in Q3 2025, and -$1.2 million in Q2 2025.